A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF QUIZARTINIB (AC220) IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY, AND MAINTENANCE THERAPY IN PATIENTS 18 TO 70 YEARS OLD WITH NEWLY DIAGNOSED FLT3-ITD (+) ACUTE MYELOID LEUKEMIA

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Daiichi Sankyo

Protocol Number
AC220-A-U302

To Learn More Call
201-510-0910